Selpercatinib and pralsetinib, tyrosine-kinase inhibitors with a high specificity for RET protein, recently obtained FDA approval for the treatment of Lung and Thyroid Cancers with RET gene mutations or fusions. The gene discussed is RET; the disease is thyroid cancer.